Literature DB >> 20005940

Activation of human neutrophils by titanium dioxide (TiO2) nanoparticles.

D M Gonçalves1, S Chiasson, D Girard.   

Abstract

This paper describes the in vitro effects of titanium dioxide (TiO(2)) nanoparticles (NPs) upon human neutrophils. Kinetic experiments revealed no cell necrosis after 24h of treatment with TiO(2) (0-100 microg/ml). In contrast, TiO(2)-induced change in cellular morphology in a concentration-dependent manner in neutrophils over time, indicating its potential to activate these cells. To further support this, we demonstrated that TiO(2) markedly and rapidly induced tyrosine phosphorylation events, including phosphorylation of two key enzymes, p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinases-1/2 (Erk-1/2). We also determined the effects of TiO(2) on two neutrophil functions requiring a longer exposure period between NPs and cells: apoptosis and cytokine production. Interestingly, at concentrations >or=20 microg/ml, TiO(2) inhibited neutrophil apoptosis in a concentration-dependent manner after 24h of treatment. Supernatants from TiO(2)-induced neutrophils were harvested after 24h and tested for the presence of 36 different analytes (cytokines, chemokines) using an antibody array assay. TiO(2) treatment increased production of 13 (36%) analytes, including IL-8, which exhibited the greatest increase ( approximately 16 x control cell levels). The increased production of IL-8 was confirmed by ELISA. We conclude that TiO(2) exerts important neutrophil agonistic properties in vitro. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005940     DOI: 10.1016/j.tiv.2009.12.007

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  30 in total

Review 1.  Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development.

Authors:  Lázaro Moreira Marques Neto; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  Front Immunol       Date:  2017-03-08       Impact factor: 7.561

Review 2.  Mechanisms of immune response to inorganic nanoparticles and their degradation products.

Authors:  Raziye Mohammapdour; Hamidreza Ghandehari
Journal:  Adv Drug Deliv Rev       Date:  2021-11-02       Impact factor: 15.470

3.  Evaluating the Apoptotic Cell Death Modulatory Activity of Nanoparticles in Men and Women Neutrophils and Eosinophils.

Authors:  Marion Vanharen; Isabelle Durocher; Abdelaziz Saafane; Denis Girard
Journal:  Inflammation       Date:  2021-09-18       Impact factor: 4.092

Review 4.  Activation of Human Eosinophils with Nanoparticles: a New Area of Research.

Authors:  Marion Vanharen; Denis Girard
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

Review 5.  Titanium dioxide nanoparticles: a review of current toxicological data.

Authors:  Hongbo Shi; Ruth Magaye; Vincent Castranova; Jinshun Zhao
Journal:  Part Fibre Toxicol       Date:  2013-04-15       Impact factor: 9.400

6.  Inhibition of angiogenesis- and inflammation-inducing factors in human colon cancer cells in vitro and in ovo by free and nanoparticle-encapsulated redox dye, DCPIP.

Authors:  Fadee G Mondalek; Sivapriya Ponnurangam; Janita Govind; Courtney Houchen; Shrikant Anant; Panayotis Pantazis; Rama P Ramanujam
Journal:  J Nanobiotechnology       Date:  2010-07-15       Impact factor: 10.435

7.  [Risk assessment of nanoparticles in consumer products].

Authors:  S Hackenberg
Journal:  HNO       Date:  2014-06       Impact factor: 1.284

8.  Nano-TiO₂ particles impair adhesion of airway epithelial cells to fibronectin.

Authors:  Sotirios G Zarogiannis; Aristotelis S Filippidis; Solana Fernandez; Asta Jurkuvenaite; Namasivayam Ambalavanan; Andrei Stanishevsky; Yogesh K Vohra; Sadis Matalon
Journal:  Respir Physiol Neurobiol       Date:  2012-08-28       Impact factor: 1.931

9.  Naringenin mitigates titanium dioxide (TiO2)-induced chronic arthritis in mice: role of oxidative stress, cytokines, and NFκB.

Authors:  Marília F Manchope; Nayara A Artero; Victor Fattori; Sandra S Mizokami; Dimitrius L Pitol; João P M Issa; Sandra Y Fukada; Thiago M Cunha; José C Alves-Filho; Fernando Q Cunha; Rubia Casagrande; Waldiceu A Verri
Journal:  Inflamm Res       Date:  2018-10-28       Impact factor: 4.575

10.  Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles.

Authors:  Maria-Argyro Karageorgou; Dimosthenis Stamopoulos
Journal:  Sci Rep       Date:  2021-05-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.